

# Management of Hyperthyroidism in Adults in India



# Management of Hyperthyroidism in Adults in India

**Shashank Joshi<sup>1</sup>, Krishna Seshadri<sup>2</sup>, Sujoy Ghosh<sup>3</sup>, Pramila Kalra<sup>4</sup>, Arun S Menon<sup>5</sup>, Himagirish K Rao<sup>6</sup>, Mini G Pillai<sup>7</sup>, Sarita Bajaj<sup>8</sup>, Rajesh Rajput<sup>9</sup>**

1 - Consultant Endocrinologist, Department of Endocrinology, Joshi Clinic and Lilavati Hospital and Research Centre, Mumbai, India

2 - Consultant Endocrinologist, Chennai Diabetes and Endocrine Clinic, Chennai, Tamil Nadu<sup>8</sup>

3 - Department of Endocrinology and Metabolism, Institute of Post-Graduate Medical Education and Research, Kolkata, West Bengal, India

4 - Department of Endocrinology, M. S. Ramaiah Medical College, Bangalore, Karnataka, India.

5 - Department of Endocrinology, Amrita Institute of Medical Sciences and Research Centre, Kochi, Kerala, India.

6 - Clinic of General Surgery, St. Johns Medical College Hospital, Bengaluru, India

7 – Consultant Endocrinologist, Lakshmi Hospital, Ernakulam, Kochi, Kochi

8- Consultant Endocrinologist, Former Director-Professor and Head, Department of Medicine, MLN Medical College, Prayagraj, Uttar Pradesh, India.

9 - Department of Endocrinology, Pt. B. D. Sharma PGIMS, Rohtak, Haryana, India.

## Management of Hyperthyroidism in Adults in India

**Shashank Joshi<sup>1</sup>, Krishna Seshadri<sup>2</sup>, Sujoy Ghosh<sup>3</sup>, Pramila Kalra<sup>4</sup>, Arun S Menon<sup>5</sup>, Himagirish K Rao<sup>6</sup>, Mini G Pillai<sup>7</sup>, Sarita Bajaj<sup>8</sup>, Rajesh Rajput<sup>9</sup>**

1 - Consultant Endocrinologist, Department of Endocrinology, Joshi Clinic and Lilavati Hospital and Research Centre, Mumbai, India

2 - Consultant Endocrinologist, Chennai Diabetes and Endocrine Clinic, Chennai, Tamil Nadu<sup>8</sup>

3 - Department of Endocrinology and Metabolism, Institute of Post-Graduate Medical Education and Research, Kolkata, West Bengal, India

4 - Department of Endocrinology, M. S. Ramaiah Medical College, Bangalore, Karnataka, India.

5 - Department of Endocrinology, Amrita Institute of Medical Sciences and Research Centre, Kochi, Kerala, India.

6 - Clinic of General Surgery, St. Johns Medical College Hospital, Bengaluru, India

7 - Consultant Endocrinologist, Lakshmi Hospital, Ernakulam, Kochi, Kochi

8 - Consultant Endocrinologist, Former Director-Professor and Head, Department of Medicine, MLN Medical College, Prayagraj, Uttar Pradesh, India.

9 - Department of Endocrinology, Pt. B. D. Sharma PGIMS, Rohtak, Haryana, India.

### Objectives

In India the prevalence of hyperthyroidism ranges from 0.9% to 1.5%. Suboptimal diagnosis and management in patients with hyperthyroidism may lead to complications which may be life-threatening. There is a need for a comprehensive clinical practice recommendations to optimize patient care and improve patient outcomes.

### Methods

The Indian Thyroid Society (ITS) clinical practice recommendations have been formulated based on consultation with expert endocrinologists of India after examination of relevant evidence using a systematic literature search approach.

### Results

The ITS clinical practice recommendations include 4 distinct sections: (1) Introduction; (2) Diagnosis; (3) Management of Hyperthyroidism which includes the role of beta-blockers, management of Graves' disease, multinodular goiter, toxic adenoma (4) Sections on thyroiditis, thyroid storm and hyperthyroidism in women with considerations to pregnancy and lactations have also been included

### Conclusion

Evidence based recommendations have been developed to optimize treatment in patients with hyperthyroidism with emphasis on diagnosis and optimizing treatment. Accurate diagnosis is a precedent to etiology-based management protocols for the achievement of euthyroidism while minimizing complications. Anti-thyroid drugs are the first line treatment in Graves' hyperthyroidism management. One notable new theme is the maintenance treatment of Graves' disease patients on the lowest possible dose to maintain euthyroidism for long duration (5 years). Multinodular goiter and toxic adenoma also require control of thyrotoxicosis with antithyroid drugs in the initial phase. Long term antithyroid drugs are now considered in multinodular goiter in patients not suitable for radioactive iodine or surgery. Management of special cases of hyperthyroidism including amiodarone induced thyroiditis, hyperthyroidism in pregnancy and thyroid storm have been discussed. The recommendations provide guidance in the management of patients with hyperthyroidism to facilitate clinical decision making of health care professionals in the management of patients with hyperthyroidism.

# Hyperthyroidism Overview in Adults

## Contents

1. Introduction.....	5
1.1 Prevalence.....	5
1.2 Etiopathogenetic Causes of Thyrotoxicosis .....	5
2. Diagnosis .....	7
2.1 Clinical Diagnosis .....	7
2.2 Serology .....	9
2.2.1 Thyroid Function Test .....	9
2.2.2 TRAb Immunoassay .....	9
2.3 Imaging .....	10
2.3.1 Thyroid Ultrasonography .....	10
2.3.2 Thyroid Scintigraphy.....	10
3. Management of Hyperthyroidism .....	11
3.1 Role of Beta-blockers in initial management.....	11
3.2 Management of Graves' Disease .....	12
3.2.1. Medical Management .....	12
3.2.2. Dosing, Titration and Duration .....	13
3.2.3. Low Dose Anti-thyroid Drug.....	16
3.2.4. Block and Replace .....	16
3.2.5. Biochemical Goal of treatment .....	16
3.2.6. Follow up .....	17
3.2.7. Adverse events and when to expect” .....	17
3.2.8. Medical Treatment Outcomes .....	18
3.2.9. Radioiodine therapy (RAI) in Graves' Disease .....	19
3.2.10. Surgery .....	21
3.3 Graves' Ophthalmopathy/Orbitopathy .....	23
3.3.1. Management of Graves' ophthalmopathy/ orbitopathy: .....	23
3.4 Multinodular Goiter.....	26
3.5 Toxic Adenoma .....	28
4. Thyroiditis .....	30
5. Thyroid Storm” .....	33
6. Clinical Considerations for women of childbearing potential group: .....	35

## 1.Introduction

Hyperthyroidism is a state of thyrotoxicosis due to intrinsic thyroid gland hyperfunction leading to increased synthesis and high circulating thyroid hormone. Thyrotoxicosis is the clinical state as a result of increased thyroid hormones in the body originating from any cause.<sup>i</sup> Hyperthyroidism is classified as either subclinical or overt. Reduced serum TSH levels and increased levels of free serum T3 and/or free T4 indicate overt hyperthyroidism. Reduced serum TSH levels and normal serum levels of free T3 and free T4 indicate subclinical hyperthyroidism.<sup>i</sup> If uncontrolled, hyperthyroidism can result in osteoporosis, congestive heart failure, atrial fibrillation, embolic events, tremors, weakness, neuropsychiatric symptoms, negative pregnancy outcomes and increased mortality rates.<sup>ii</sup>

### 1.1 Prevalence

Globally, 0.2-1.3% of the population suffers from hyperthyroidism.<sup>iii</sup> In India the prevalence of hyperthyroidism ranges from 0.9% to 1.5% in people living in community.

### 1.2 Etiopathogenetic Causes of Thyrotoxicosis<sup>iv</sup>

**Excessive TSH receptor stimulation:** Graves' hyperthyroidism, hCG-related thyrotoxicosis, and TSH adenoma.

**Autonomous thyroid hormone secretion:** Toxic multinodular goiter and Solitary toxic adenoma, in which thyroid gland nodules secrete excess hormones. Other causes include familial or sporadic non-autoimmune hyperthyroidism.

**Destructive thyroiditis:** Subacute de Quervain, silent thyroiditis, post-partum thyroiditis, acute suppurative thyroiditis and Drug-induced thyroiditis (iodide, amiodarone, cytokine, tyrosine-kinase inhibitors, and immune checkpoint inhibitors -induced thyrotoxicosis).

**Extrathyroidal sources of thyroid hormone:** Thyrotoxicosis factitial, hamburger thyrotoxicosis, struma ovarii (rare) and metastases of differentiated thyroid cancer (rare).

The four major causes of thyrotoxicosis are Graves' disease, Multinodular goiter, Toxic adenoma and thyroiditis.<sup>iv</sup> In India, Graves' disease comprise of 59.3% of Indian hyperthyroid cases, multinodular goiter 36.4% and toxic adenoma 4.3%.<sup>v</sup>

### **1. Graves' disease:**

Graves' disease (GD) is the most common cause of hyperthyroidism. It is an autoimmune disease characterized by presence of Thyrotropin Receptor Antibodies (TRAb) also known as Thyroid stimulating hormone receptor (TSHR) autoantibodies which activate TSH receptors, resulting in excessive thyroid hormone synthesis. GD is more common in women. Approximately 30% of patients have family members who have GD or Hashimoto's thyroiditis. Environmental factors such as smoking, increased iodine intake, stress, and pregnancy can all contribute to hyperthyroidism.<sup>iv</sup> Graves' ophthalmopathy, pretibial myxedema, thyroid acropachy, and exophthalmos are characteristic of GD.<sup>vi</sup>

### **2. Toxic multinodular goiter (Plummer Disease)**

In multinodular goiter, follicular cells that are genetically heterogeneous as well as acquisition of inheritable qualities lead to loss of anatomical and functional integrity of the follicles. These follicular cells when acted on by elevated TSH or external events such as cycles of iodine deficiency and repletion, goitrogens, inborn errors of thyroid hormone synthesis, local growth regulating factors of the tissues lead to follicular proliferation. Growth and fusion of the follicles, lead to formation of nodules and may be detected as a mass in the neck.<sup>vii</sup> Toxic multinodular goiter is more common in older adults (aged >50 years) compared to GD. Unlike GD, toxic nodular goiter is progressive (except in cases triggered by excessive iodine intake).<sup>viii</sup>

### **3. Toxic Adenoma**

Thyroid gland adenomas are non-cancerous tissue growths caused due to somatic activating mutations of genes regulating growth and thyroid hormone synthesis. Toxic adenomas could be dormant or active. Active adenomas producing excessive thyroid hormones are known as toxic thyroid adenomas.<sup>ix</sup> It is a single hyper-functioning nodule in the thyroid gland, results in localized excess thyroid hormone production, commonly found in patients aged 30-60 years.<sup>iv</sup>

### **4. Thyroiditis**



Thyroiditis is characterized by inflammation of the thyroid tissue, which causes preformed hormones to be released into the bloodstream.<sup>iv,x</sup>

## 2. Diagnosis

### 2.1 Clinical Diagnosis

Diagnosis may be delayed or missed in hyperthyroidism, because its symptoms can manifest across various organ systems, making it easily confounded with other health issues.<sup>xi, xii</sup>

*Table 2: Signs and Symptoms of Hyperthyroidism<sup>iv,v</sup>*

System	Symptoms	Signs
General	Weight loss	Increased sweating
	Fatigue	Hoarseness of voice
	Weakness esp. in elderly	
	Heat intolerance	
	Increased appetite	
Cardiovascular	Palpitations	Tachycardia with/without irregular rhythm
	Ankle edema	Atrial fibrillation
		Wide pulse pressure
		Systolic Hypertension
		Heart failure
Neuropsychiatry	Restlessness, Anxiety	Brisk tendon reflexes
	Sleep disturbances	Finger or tongue tremor
	Depression	Muscle wasting
	Poor concentration	
	Tremors	
	Muscle weakness	
Reproductive	Periodic Paralysis	
	Oligomenorrhea,	Subfertility in women
	Irregular menstrual cycles	

	Impaired libido in men	
<b>Gastrointestinal</b>	Loose stools, diarrhea, nausea	Increase in frequency of bowel movements
<b>Musculoskeletal</b>	Fragility fractures	Unexplained osteoporosis
<b>Endocrinology</b>	Goiter	Gynaecomastia
		Pretibial myxoedema
<b>Ophthalmology</b>	Bulging eyes	Upper lid retraction
	Stare	
<b>Dermatology</b>		Plummer's nail
		Warm moist skin

Symptoms of hyperthyroidism may also include urinary symptoms one to six months after onset of other symptoms. Reduced flow rates increased post-void residual volume, enlarged bladder capacity and increased perineal muscle electromyographic activity has been observed.<sup>xiii</sup>

**Apathetic hyperthyroidism** is characterized by weakness, weight loss, lethargy, depression and arrhythmia. Since this presentation of hyperthyroidism is commonly seen in the middle aged and the elderly, the associated signs and symptoms may be mistaken as the natural process of aging. Decreased FT3/FT4 ratio, increased alanine aminotransferase (ALT) levels and bone-specific alkaline phosphatase (BAP) levels were associated with apathetic hyperthyroidism.<sup>xiv</sup>

Individuals with suspected or confirmed hyperthyroidism require a detailed medical history and comprehensive physical examination. Vital signs should be assessed. Examination of the thyroid gland for size, tenderness, symmetry, and nodularity is important, along with evaluating pulmonary, cardiac, and neuromuscular function. Presence or absence of peripheral oedema, eye signs, or pretibial myxedema should be noted.<sup>iv,viii</sup> If a patient presents with a symmetrically enlarged thyroid, recent onset of orbitopathy, and moderate to severe hyperthyroidism, Graves' disease (GD) is likely, and diagnosis may be based on clinical presentation only.<sup>viii, xv</sup>

S. No	Key summary point
1.	Hyperthyroidism may have a heterogenous presentation with symptoms manifesting across various organ systems. To avoid delay in diagnosis which leads to complications, a high degree of clinical suspicion is required. Any person with



suspicion of hyperthyroidism must undergo thyroid function test. TSH <0.01 mIU/L with elevated free T4 and free T3 are indicative of overt hyperthyroidism
--

## 2.2 Serology

### 2.2.1 Thyroid Function Test

Hyperthyroidism can be diagnosed with thyroid function testing (TFT). Initial assessment should include evaluation of serum levels of TSH, free T4, and total T3.<sup>viii</sup> In overt hyperthyroidism, serum levels of free T4, T3, or both are elevated, while serum TSH level is decreased, falling below 0.01 mU/L.<sup>viii</sup> If diagnosis isn't clear from the clinical presentation and initial biochemical assessment, further diagnostic testing is recommended:

- Assessing levels of TRAb (thyrotropin receptor antibodies)
- Examining thyroidal blood flow using thyroid ultrasonography
- Determining radioactive iodine uptake (RAIU)

### 2.2.2 TRAb Immunoassay

TRAb is sensitive and specific assay for accurate diagnosis and monitoring of Graves' disease (GD). Sequential monitoring of TRAb can be used to guide duration of antithyroid drug (ATD)<sup>xvi</sup> Negative or low-titer thyroid receptor antibody have a high likelihood of remission and can be used as the deciding factor to discontinue antithyroid drug treatment.<sup>xvii</sup>

TRAb assessment is crucial in pregnant women with suspected Graves' Disease, history of GD, past treatments like radioactive iodine ablation or surgery, or previous instances of fetal thyroid dysfunction. TRAb assessment helps in the differentiation Graves' disease versus gestational hyperthyroidism, especially during the early stages of pregnancy. Initial TRAb levels should be measured in the first trimester, if elevated, is measured again at 18-22 weeks of gestation<sup>xviii, xviii</sup> If maternal TRAb concentration remains high (>3 times the cut off), monitoring of fetus for thyroid dysfunction throughout pregnancy is recommended.<sup>xix</sup>

Measuring functional TRAb is vital for diagnosing, differentiating, and monitoring GO.<sup>xx</sup> Patients who are at high risk for deterioration of GO are associated with a high serum TRAb level.

Patients who are on high dose (>100 mg/day) biotin supplementation can lead to falsely high T3 and T4 levels and low TSH levels. Biotin may also result in false positive TRAb levels. Biotin should be stopped for 2 to 7 days before testing. <sup>xxi</sup>

## 2.3 Imaging

### 2.3.1 Thyroid Ultrasonography

Thyroid Ultrasonography (USG) offers swift and non-invasive evaluation without ionizing radiation exposure. GD is recognized by diffuse thyroid enlargement and hypoechogenicity. Colour-flow or power Doppler examination helps in identifying vascular patterns and quantifying thyroid vascularity. In untreated GD, the thyroid vascularity is increased in multiple small areas which shows a pulsatile pattern entitled as “thyroid inferno”. Elevated thyroid artery flow velocity and peak systolic velocity (PSV) are seen in untreated GD. The elevated PSV can distinguish GD from subacute thyroiditis or amiodarone-induced thyrotoxicosis type 2 where the blood flow is reduced. In nodular disease, ultrasonography can help identify thyroid nodules.

USG findings combined with positive TRAb can obviate the need for scintigraphy, yet the latter remains useful in certain instances, especially before radioactive iodine (RAI) treatment. USG with colour flow Doppler serves as a valuable alternative when RAI is contraindicated. <sup>ii,viii</sup>

### 2.3.2 Thyroid Scintigraphy

Thyroid uptake Scintigraphy evaluation is recommended in the case of palpable thyroid nodules or if the etiology is unclear after TRAb testing. This is done using radioiodine uptake or technetium-99m pertechnetate. Radioactive iodine uptake scans show a diffuse uptake in Graves’ Disease, a focal uptake in toxic adenoma or nodules, absent/no uptake in thyroiditis, extra-thyroidal thyroid hormone production and in high iodine exposure cases. <sup>xxii</sup>

In the evaluation of ectopic thyroid tissue and multiple thyroid nodules, positron emission tomography (PET)/ Single photon emission Computed Tomography SPECT/(-CT) or PET/SPECT/ ultrasonography may be an effective diagnostic tool. Technetium-99m-methoxyisobutylisonitrile or [<sup>99m</sup>Tc] MIBI can assist in isolating the type of amiodarone induced thyroiditis. <sup>xxiii</sup> 8F-fluorodeoxyglucose (18F-FDG) PET scan (<sup>18</sup>F-FDG-PET/CT scan) may have a

role in the diagnosis of autoimmune thyroid disease (AITD) such as Graves' disease, Hashimoto's thyroiditis or atrophic autoimmune hypothyroidism. There is an increase in standardized uptake value in the thyroid parenchyma in these conditions. <sup>xxiv</sup>

S. No	Key summary point
2.	The etiology of hyperthyroidism must be delineated. Thyroid receptor antibody (TRAb) immunoassay is diagnostic for Graves' disease. Radioactive iodine uptake scintigraphy imaging shows differential pictures for Graves' disease, toxic multinodular goiter, toxic adenoma or thyroiditis. Thyroid ultrasonography enhanced with colour-flow or power doppler examination can help identify Graves' disease and thyroiditis

### 3. Management of Hyperthyroidism

#### 3.1 Role of Beta-blockers in initial management

Beta-adrenergic blockade is recommended for managing the adrenergic symptoms of thyrotoxicosis, in all patients, particularly elderly individuals, those with resting heart rates exceeding 90 beats per minute or coexisting cardiovascular disease. In patients with bronchospastic asthma, beta-blockers are contraindicated. Calcium Channel Blockers -Verapamil (240 mg oral or 5-10 mg intravenous)<sup>xxv</sup> and Diltiazem (60 mg, orally four times a day)<sup>xxvi</sup>- can offer rate control in patients who are not candidates for beta blockers.<sup>viii</sup>

*Table 4: Beta-Adrenergic Receptor Blockade in the Treatment of Thyrotoxicosis<sup>viii</sup>*

Drug <sup>a</sup>	Dosage	Frequency	Considerations
Propanolol	10-40 mg	3-4 times per day	Non-selective $\beta$ -adrenergic receptor blockade Longest experience May block T4 to T3 conversion at high doses Preferred agent for nursing and pregnant mothers
Atenolol	25-100 mg	1-2 times per day	Relative $\beta_1$ selectivity Increased compliance Avoid during pregnancy
Metoprolol <sup>b</sup>	25-50 mg	2-3 times per day	Relative $\beta_1$ selectivity
Nadolol	40-160 mg	1 time per day	Non-selective $\beta$ -adrenergic receptor blockade Once daily Least experience to date May block T4 to T3 conversion at high doses
Esmolol	IV pump 50 - 100 $\mu$ g/kg/min		In intensive care unit setting of severe thyrotoxicosis or storm

- a- Each of these drugs are approved for treatment of cardiovascular diseases, but to date none has been approved for the treatment of thyrotoxicosis
- b- Available in once daily preparation

Among  $\beta$ -blockers, propranolol offers a distinctive dual mechanism of action. The L-isomer of propranolol effectively blocks beta receptors, addressing palpitations, anxiety, heat intolerance, and tremors. The D-isomer inhibits thyroxine deiodinase, impeding the conversion of T4 to T3 and providing some therapeutic benefit.<sup>xxvii</sup> High doses of propranolol (40 mg four times daily) inhibit peripheral conversion of T4 to T3.<sup>ii</sup>

Beta blockers are only required for the initial symptomatic six to eight weeks as they do not appear to alter the synthesis or secretion of the thyroid hormones. Beta-blockers are beneficial during the early stages before ATDs achieve their therapeutic efficacy.<sup>xxviii, xxix</sup>

### 3.2 Management of Graves' Disease

The goal in the management of Graves' Disease (GD) is to restore euthyroidism. Presence of goiter and/or Graves' ophthalmopathy/ orbitopathy (GO) also impact treatment decisions. Three effective options for Graves' disease are antithyroid drugs (ATDs), radioactive iodine (RAI) therapy, or thyroidectomy.<sup>viii</sup> Surgery or RAI destroy the thyroid tissue to restore euthyroidism. ATDs on the other hand prevent thyroid hormone synthesis to achieve euthyroidism thereby preserving the thyroid structure.<sup>xxx</sup>

*Table 5: Candidates for Anti-Thyroid Drugs*

Candidates for Anti Thyroid Drugs:
<ul style="list-style-type: none"> <li>• Patients with high likelihood of remission (mild disease, small goiters, and negative or low-titer TRAb);</li> <li>• pregnancy;</li> <li>• the elderly or comorbidities increasing surgical risk or with limited life expectancy;</li> <li>• individuals in nursing homes or other care facilities</li> <li>• previously operated or irradiated necks;</li> <li>• lack of access to a high-volume thyroid surgeon;</li> <li>• moderate to severe active Graves' ophthalmopathy/ orbitopathy ;</li> <li>• Patients who need more rapid biochemical disease control.</li> </ul>

#### 3.2.1. Medical Management

ATDs represent the mainstay of therapy in most regions, including Europe, Asia, and the United States. It is first-line treatment for GD, particularly in younger patients with mild or uncomplicated disease. ATDs includes such as carbimazole (CBZ), methimazole (MMI), and propylthiouracil (PTU). These medications work by reducing the production of thyroid hormone. They interfere with the function of thyroperoxidase, an enzyme crucial for iodide organification and inhibit the coupling of iodotyrosines. Studies have shown that ATDs not only decrease thyroid hormone levels but also reduce elevated TRAb levels in Graves' disease.<sup>ii</sup>

Carbimazole is the preferred first line ATD in non-pregnant individuals. Carbimazole has been available in India since 1963.<sup>xxxi</sup> The Indian National List of Essential Medicines (NLEM) includes carbimazole for wider accessibility, even at the primary healthcare level.<sup>xxxii</sup> Carbimazole offers a dose finer titration compared to methimazole<sup>1</sup>. This is an added advantage in the treatment of hyperthyroidism where carefully dose optimized treatment is required. Carbimazole may even result in fewer cases of iatrogenic hypothyroidism and use of concomitant supplemental T4<sup>2xxx</sup>

The mechanism of action of PTU is similar to that of carbimazole and methimazole. Additionally, it acts by inhibiting the peripheral conversion of thyroxine (T4) to triiodothyronine (T3). However, this effect is considered marginally beneficial except in cases of severe thyrotoxicosis. The shorter half-life of PTU compared to CBZ and MMI makes it less practical for long-term management.<sup>ii</sup>

### 3.2.2. Dosing, Titration and Duration<sup>xxxiii</sup>

#### **Dosing:**

The initial dose of CBZ or MMI should be adjusted according to the severity of hyperthyroidism, and it should be roughly estimated based on the baseline levels of free T4 hormone.<sup>xxxiv</sup>

*Table 6: Initial dose of Anti-thyroid drugs in the treatment of hyperthyroidism<sup>xxxv</sup>*

<sup>1</sup> Carbimazole doses of 60 mg, 45 mg, 40 mg, 30 mg, 25 mg, 20 mg, 15 mg, 10 mg and 5 mg have a Calculated active metabolite of 36 mg, 27 mg, 24 mg, 18 mg, 15 mg, 12 mg, 9 mg, 6 mg, and 3 mg which offers finer titration than methimazole (multiples of 5 mg and 10 mg)

<sup>2</sup> In Baek et al, one of the main reason for the change in ATD from methimazole to carbimazole was for further reduction in ATD dose. Carbimazole (n=38) with mean dose 2.3 mg (at the time of stopping of ATD) for a duration of 36 months compared to Methimazole (n=166) with mean dose of 3 mg for a duration of 30 months decreased the risk of relapse (HR 0.248, P = 0.004).

Free T4 elevation	CBZ (mg)	MMI (mg)	PTU (mg)
<b>1-1.5 x ULN</b>	10-15	5-10	100-200
<b>1.5-2 x ULN</b>	20-30	10-20	200-400
<b>2-3 x ULN</b>	50-70	30-40	600-800

ULN – Upper Limit of Normal

#### Rationale for initial dose:

Carbimazole rapidly converts to methimazole which concentrates in the thyroid gland. Starting with higher doses can bring the disease under control faster, especially in cases where quick stabilization is necessary. <sup>xxxvi, xxxvii</sup>

#### Single dose Regimen for Carbimazole

Single dose carbimazole in dose of 30 mg has been shown to be efficacious and can improve patient compliance in the initial treatment of hyperthyroid Graves' disease patients with attainment of clinical euthyroidism and normalization of serum T4 levels within 1-3 months. <sup>xxxviii, xxxix</sup>

#### **Titration:**

After initiation of the treatment, thyroid function tests are often reviewed 3-4 weeks later to titrate the dose based on free T4 and free T3 levels. A significant proportion of patients achieve euthyroidism within this period. TSH levels often remain suppressed for several months and therefore do not provide a sensitive index of early treatment response. <sup>ii</sup>

The titration regimen is often preferred where dose is down-titrated in accordance with the cascading TFT results. Carbimazole is initially dosed at 10-40mg daily and titrated until maintenance of 5-15mg is achieved. <sup>xi, xli</sup> As anti-thyroid therapy is initiated, thyroid hormone secretion decreases, and the drug dose should be decreased to avoid hypothyroidism. <sup>xi</sup> In Yap et al, a single daily dose of 15 mg carbimazole was seen to be as effective as conventional doses of 5 mg thrice daily in the maintenance phase of treatment. <sup>xli</sup>



Lowering the medication dosage without causing thyrotoxicosis to worsen indicates a reduction in disease activity. This may be due to a decrease in the production of TRABs. Additionally, the treatment goal shifts from complete inhibition of T4 and T3 synthesis to only partial inhibition.<sup>xi</sup>

Factors that can predict a low remission rate before beginning the treatment: large goiter, Graves' ophthalmopathy/ orbitopathy (GO), high thyroglobulin levels, high levels of TSHR-Ab and pretibial myxedema.<sup>xxxiv</sup> Factors can indicate poor responsiveness: persistently low TSH levels or high TSHR autoantibody levels lasting typically more than one year.<sup>xxxiv</sup>

*Table 7: Duration Recommendation for Graves' Disease*

ATA guidelines (2016) viii	<ul style="list-style-type: none"> <li>• If CBZ or MMI is chosen as the primary therapy for GD, the medication should be continued for approximately <b>12–18 months</b>.</li> <li>• Discontinue CBZ or MMI if TSH and TRAb levels are normal at that time.</li> </ul>
ETA guidelines (2018) <sup>ii</sup>	<ul style="list-style-type: none"> <li>• The optimal duration of ATD therapy for the titration regimen is <b>12–18 months</b>.</li> </ul>
NICE guidelines (2019) <sup>xxxiii</sup>	<ul style="list-style-type: none"> <li>• When offering antithyroid drugs as first-line definitive treatment to adults with GD, CBZ should be offered for <b>12 to 18 months</b>.</li> <li>• Use either a block and replace or a titration regimen during this period.</li> <li>• Review the need for further treatment after 12 to 18 months.</li> </ul>

#### Rationale for 12-18 months' duration:

Antithyroid drug therapy often leads to the normalization of TRAb levels over time in many patients, which plays a significant role in achieving remission after long-term treatment.<sup>ii,xxxv,xxxvi</sup>

- Reported remission rates, defined as achieving euthyroidism one year after discontinuing treatment are around 50%-55% after an initial 12 to 18 months of antithyroid drug therapy.
- TRAb titers typically decrease during antithyroid drug therapy and resolve in 70% to 80% of patients within 18 months of treatment.
- However, if the patient continues to test positive for TRAb, the likelihood of remission is much lower, ranging from 0% to 20%.

In Garcia et al, in one group, 50 subjects with Graves' disease were given carbimazole and 3 subjects were given methimazole in the range of 2.5 to 5 mg for 10 to 12 months achieved euthyroidism. These patients were continued on the same low dose for a period of 5 years. The

relapse rate in this group of subjects was 22.64%. This was significant when compared to a 77.45% relapse rate in the comparator group of 31 subjects who were also on low dose of anti-thyroid drugs who achieved euthyroidism in 10-12 months but stopped ATD thereafter. <sup>xlii</sup>

In Azizi *et al*, the findings revealed that after a 5-year regimen of methimazole therapy, a persistent normalisation of thyroid-stimulating hormone receptor antibodies (TRAb) was observed. Furthermore, the study noted that ATD treatment extending beyond 60 months yielded a remission rate of 85% over 4 years. The research concluded that long-term ATD therapy (>60 months) exhibited both safety and effectiveness, highest remission rates and often leading to the complete resolution of GD symptoms in most patients. <sup>xliii, xliv</sup>

### 3.2.3. Low Dose Anti-Thyroid Drug

An important aspect of medical management of patients with Graves' Disease and Graves' Ophthalmopathy include prevention of iatrogenic hypothyroidism. <sup>xlv</sup> This may be achieved by reducing the antithyroid medications to a minimum of 2.5 mg during the maintenance phase. <sup>xlvi</sup> Furthermore, some people are extremely sensitive to low doses, therefore even 2.5-5 mg CBZ/day may be required to maintain control. <sup>xlvi</sup>

### 3.2.4. Block and Replace

The 'block and replace' therapy is an alternative to titration-based monotherapy. Upon achievement of euthyroidism, using Carbimazole (dosage 30-40 mg once daily), thyroxine replacement therapy (100-125 µg daily) is initiated. This prevents iatrogenic hypothyroidism. Treatment last six months, or may be extended, particularly in the presence of significant thyroid ophthalmological disease. Some clinicians use this strategy in case of alterations in thyroid function throughout the treatment. Patients with Graves' Alternans, who alternate between hyperthyroidism and hypothyroidism status, may have thyroid stimulating hormone receptor (TSHR) blocking autoantibodies that fluctuate over time, which can be difficult to manage clinically. In such cases, the 'block and replace' strategy can be beneficial in delivering both ATDs and levothyroxine parallelly. <sup>xxxiv, xl</sup>

### 3.2.5. Biochemical Goal of treatment

During every visit of follow up, dose of the anti-thyroid drug must be titrated and adjusted according to the free T4 and T3 levels. The serum concentration of the free T4 and T3 should be

targeted to the middle range of normal values in non-pregnant adults with hyperthyroidism. Further, once the TSH has been normalized, it should be maintained within the reference range.<sup>xlvi</sup>

### 3.2.6. Follow up<sup>ii,viii</sup>

Adults using antithyroid medications for hyperthyroidism should consider:

- Assessment of FT4 and total T3 levels 2-6 weeks after starting therapy to determine the severity of thyrotoxicosis and alter drug dosage accordingly
- Monitoring of serum T3 levels should also be done as free T4 levels may normalize despite persistent elevated serum total T3 levels
- Monitoring of TSH, FT4, and FT3 levels every 6 weeks until TSH is normalised
- Monitoring of TSH (with cascading) every 3 months until antithyroid medications are discontinued
- For patients undergoing long-term anti-thyroid drug (ATD) (>18 months), the interval can be extended to 6 months.
- For patients who have stopped ATD, consider routine monitoring with
  - TSH within 2 months of stopping ATD, then
  - TSH every 3 months for 1 year, then
  - TSH once a year

### 3.2.7. Adverse events and when to expect<sup>xliv,li</sup>

*Table 9: Adverse events associated with anti-thyroid drugs*

Within the first few weeks of treatment initiation	Approximately 5 weeks	Within the initial 90 days of starting treatment
1. Minor side effects, such as pruritic rash and arthralgias, occur in roughly 5%. 2. Rash may resolve with continuous medication or with antihistamines, but it	1. Hepatotoxicity (Usually cholestatic) 2. Mean time to onset: 36 days 3. Incidence <0.1%	Agranulocytosis 1. Incidence is 0.3–0.6% with a mortality rate of 21.5% 2. Dose related adverse event 3. Can also occur owing to re-exposure to the medication after several years

could be severe enough to need drug withdrawal.		4. Typical symptoms include high fever and severe pharyngitis.
3. These individuals may be switched to propylthiouracil, although 30% to 50% had a similar reaction.		5. Resolution: Immediate drug discontinuation, hospitalization, and provision of broad-spectrum antibiotics and hematopoietic growth factor treatment.

ATD therapy is definitively contraindicated in case of known significant adverse effects in the past.

Monitoring for adverse events:<sup>ii,viii,xxxiii</sup>

- Unless there is a suspicion of agranulocytosis or liver dysfunction, there is no requirement to routinely monitor the complete blood count and the liver function in patients who are on antithyroid drugs
- Patients need written instructions regarding the identification of symptoms of possible agranulocytosis which include sore throat, mouth ulcers, fever and the cessation of ATD treatment pending a differential white blood cell count

### 3.2.8. Medical Treatment Outcomes

#### Remission<sup>viii</sup>

A patient is considered to be in the remission stage if they have had normal blood TSH, free T4, and total T3 for one year after discontinuing ATD therapy. Maximum remission rates (50-55%) are attained between 12-18 months. TRAb levels should be measured before discontinuing ATD therapy because they help with treatment cessation decision making, with normal levels indicating a higher possibility of remission. Patients with consistently high TRAb levels after 12-18 months can continue carbimazole/methimazole medication and retake the TRAb test after another 12 months or can opt for RAI or thyroidectomy.

#### Relapse/Recurrence after a course of ATD<sup>ii</sup>

Relapse is most frequent in the first 6-12 months after ATD cessation but can happen years later. Patients with severe hyperthyroidism, big goiters, or persistently high TRAb levels are more prone

to relapse when medication is discontinued, although the prognosis is unpredictable. All patients should be monitored for relapse during the first year after treatment cessation, and at least once a year thereafter.

### 3.2.9. Radioiodine therapy (RAI) in Graves' Disease

Candidates for RAI are women planning a pregnancy in the future (in >6 months following RAI administration, provided thyroid hormone levels are normal), individuals with comorbidities increasing surgical risk, patients with previously operated or externally irradiated necks, lack of access to a high-volume thyroid surgeon, patients with contraindications to ATD use or failure to achieve euthyroidism during treatment with ATDs, patients with periodic thyrotoxic hypokalemic paralysis, right heart failure pulmonary hypertension, or congestive heart failure.<sup>viii</sup>

Radioiodine therapy stands as the definitive treatment of choice for many countries, particularly for patients with small goiters (<50 g) or those with challenges in managing their condition with thionamides or contraindications to such drugs. For RAI, the overarching therapeutic goal of Graves' disease is the induction of hypothyroidism. RAI effectively resolves hyperthyroidism in over 90% of patients with Graves' disease or autonomous thyroid nodules. Factors that contribute to persistent hyperthyroidism following radioactive iodine treatment for Graves' disease: male gender, prior antithyroid drug therapy, prolonged treatment duration exceeding 6 months after diagnosis, elevated levels of FT4, larger thyroid volume, and heightened radioactive iodine uptake. Achieving a euthyroid state with antithyroid drugs before radioiodine therapy is recommended.

xxi-xxxiv

For older patients and individuals with increased cardiovascular risk, it is recommended to administer  $\beta$ -blockers and initiate pretreatment with carbimazole or methimazole to mitigate the transient exacerbation of hyperthyroidism following radioiodine therapy. After achieving euthyroidism, carbimazole or methimazole administration should be discontinued 2 to 7 days before RAI treatment and may be resumed 3 to 7 days afterward. Radioactive sodium iodide ( $\text{Na}^{131}\text{I}$ ) is administered orally and accumulates in the thyroid gland. It induces significant tissue damage, resulting in the ablation of the thyroid tissue and subsequent reduction in thyroid hormone levels within 6–18 weeks. The dosage of  $^{131}\text{I}$  may either be standardized (e.g., 10 mCi or 370 MBq)



or tailored based on the size of the goiter and the uptake of radioiodine. Following the attainment of hypothyroidism, initiation of thyroid hormone replacement therapy is warranted.<sup>iv,xxi,xxxiv</sup>

Radioiodine treatment is contraindicated during pregnancy, lactation, and in patients with Graves' orbitopathy due to its potential to exacerbate the condition. Radioiodine therapy may exacerbate or induce eye disease in patients with Graves' disease, particularly those who smoke or have high TRAb levels. To mitigate this risk, pretreatment with prednisone, tapered over 3 months, is recommended for smokers, individuals with elevated TRAb levels, or those with preexisting thyroid eye disease.<sup>xxi,xxxiv</sup>

#### Monitoring of RAI treatment<sup>xxxiii</sup>

Following radioactive iodine treatment, it is recommended to monitor thyroid function by measuring TSH, FT4, and FT3 levels, every 6 weeks for the initial 6 months until TSH levels are normalized. In adults who develop hypothyroidism post-treatment and are not taking ATDs, levothyroxine replacement therapy should be initiated. The starting dosage varies based on age and cardiovascular history. Adults aged <65 years with primary hypothyroidism and no history of cardiovascular disease may be given levothyroxine (1.6 micrograms/kg body weight/day), rounded to the nearest 25 micrograms. Conversely, for adults aged ≥65 years or those with a history of cardiovascular disease, levothyroxine (lower dosage of 25-50 micrograms/ day) with titration is advised. While treating primary hypothyroidism with levothyroxine, the goal is to maintain TSH levels within the reference range. If symptoms persist, adjusting the dose of levothyroxine further may be necessary to achieve optimal well-being. However, caution should be exercised to avoid doses that cause TSH suppression or thyrotoxicosis.

It can take up to 6 months for TSH levels to return to the reference range, especially in individuals with very high initial TSH levels or a prolonged period of untreated hypothyroidism. Therefore, adjustments to the levothyroxine dose should consider this duration.

For adults with TSH levels within the reference range 6 months after radioactive iodine treatment, consider measuring TSH at 9 and 12 months after treatment. If TSH levels remain within the reference range 12 months following treatment, these should be monitored every 6 months unless hypothyroidism is developed. In cases where hyperthyroidism persists after RAI treatment,



consider using ATDs until the 6-month visit. If hyperthyroidism is present after 6 months of treatment, further treatment choices should be explored.

### 3.2.10. Surgery

Candidates for Surgery in the management for Graves' disease include women planning a pregnancy in <6 months provided thyroid hormone levels are normal, symptomatic compression or large goiters ( $\geq 80$  g); low uptake of RAI; when thyroid malignancy is documented or suspected, large thyroid nodules especially if  $>4$  cm or if nonfunctioning, or hypofunctioning on  $^{123}\text{I}$  or  $^{99\text{m}}\text{Tc}$  pertechnetate scanning; coexisting hyperparathyroidism requiring surgery especially if TRAb levels are particularly high; moderate to severe active Graves' Ophthalmopathy.<sup>viii</sup>

Thyroidectomy ensures a swift return to a euthyroid state but carries a low risk of complications (around 1-2%) like bleeding, infection, or recurrent laryngeal nerve damage affecting the voice. Complications are fewer if thyroidectomy is being performed by experienced surgeons.<sup>iv</sup> Total thyroidectomy is the preferred surgical approach for GD because it minimizes the chance of hyperthyroidism recurring compared to a subtotal thyroidectomy. However, this procedure necessitates lifelong thyroid hormone replacement therapy to compensate for the absence of thyroid gland function. In preparation for surgery, antithyroid drugs are used to induce euthyroidism and  $\beta$ -blockers are used to control cardiac rhythm. Vitamin D and calcium supplementation may be given to prevent postoperative hypocalcemia especially in patients who are at high risk of parathyroid injury. Following thyroidectomy, thyroid hormone replacement therapy is initiated to manage the hypothyroid state, with serum TSH levels monitored every 4–6 weeks postoperatively to adjust dosing as needed.<sup>xxxiv</sup>

S. No	Key summary point
3.	In cases of symptomatic thyrotoxicosis, it is necessary to initiate beta-blockers (unless contraindicated in which case calcium channel blockers are recommended) especially in patients with co-morbidities. Beta-blockers are recommended in the initial symptomatic thyrotoxic phase for a period of 6-8 weeks. Propranolol in doses of 10-40 mg given in a frequency of 3 to 4 times per day is recommended.
4.	In diagnosed patients with Graves' disease, the first line of therapy is anti-thyroid drugs. Carbimazole is the preferred anti-thyroid drug in India in non-pregnant hyperthyroidism patient.

5.	In patients with Graves' disease, the titration regimen is preferred over block and replace regimen for most cases. Initial dose is determined based on the free T4 levels and lead to normalization of free T4 within 4-6 weeks. From the initial dose, the dose is serially down titrated to the lowest maintenance dose depending on the cascading thyroid function tests every 6 weeks-3 months.
6.	The lowest maintenance dose of carbimazole may be in the range of 2.5 mg to 10 mg
7.	In Graves' disease, during follow-up in titration regimen, dose of anti-thyroid drug must be titrated and adjusted according to free T4 and free T3 levels. The serum concentration of the free T4 and free T3 should be targeted to the middle range of normal values. TSH is an unreliable biomarker for early response of the ATD treatment. Once the TSH normalizes, it should be maintained within the reference range.
8.	Anti-thyroid drugs must be continued for a period of 12 to 18 months for achieving maximum remission rate of 50-55%. Review for continuation of carbimazole must be undertaken after 12 to 18 months of treatment
9.	Antithyroid drugs may be given for more than 5 years in low maintenance dose. Long term ATD have led to a remission rate of 85% with a good safety profile. For patients undergoing long term treatment with ATD (> 18 months), the follow up interval can be 6 months
10.	For patients who have stopped ATD treatment, consider routine monitoring with TSH within 2 months of stopping ATD, then every 3 months for 1 year and then annually
11.	ATD therapy is contraindicated in case of known significant adverse effects in the past.
12.	A baseline complete blood count including white blood cell count and differential count and liver function test must be done prior to initiating ATD.
13.	Patients need written instructions regarding the identification of symptoms of possible agranulocytosis which include sore throat, mouth ulcers, fever and the cessation of ATD treatment pending a differential white blood cell count
14.	Unless there is a suspicion of agranulocytosis or liver dysfunction, there is no requirement to routinely monitor the complete blood count and the liver function in patients who are on antithyroid drugs
15.	In patients requiring radioactive iodine (RAI) treatment, it is recommended to administer beta-blockers and initiate pretreatment with anti-thyroid drugs to mitigate the transient exacerbation of hyperthyroidism following radioiodine therapy. For this regimen, carbimazole or methimazole administration should be discontinued 2 to 7 days before treatment and may be resumed 3 to 7 days afterward.
16.	The dosage of <sup>131</sup> I may either be standardized (e.g., 10 mCi or 370 MBq) or tailored based on the size of the goiter and the uptake of radioiodine. Following the attainment of hypothyroidism, initiation of thyroid hormone replacement therapy is warranted.

17.	Radioiodine treatment is contraindicated during pregnancy, lactation, and in patients with Graves' orbitopathy due to its potential to exacerbate the condition. Smokers, are at an increased risk of Graves' orbitopathy, and are also advised against radioiodine therapy.
18.	Following radioactive iodine treatment, it is recommended to monitor thyroid function in adults closely by measuring TSH, FT4, and FT3 levels, every 6 weeks for the initial 6 months until TSH levels are normalized.
19.	Total thyroidectomy is the preferred surgical approach for GD because it minimizes the chance of hyperthyroidism recurring compared to a subtotal thyroidectomy. Complications are fewer if thyroidectomy is being performed by experienced surgeons. In preparation for surgery, patients are brought to a euthyroid state with antithyroid drugs and $\beta$ -blockers.

### 3.3 Graves' Ophthalmopathy/Orbitopathy

Graves' ophthalmopathy/ orbitopathy (GO), also known as thyroid eye disease (TED) or thyroid-associated orbitopathy (TAO), is an inflammatory autoimmune illness that affects about 28% of Graves' disease (GD) patients. It typically begins between the third and fourth decades of life. Clinical manifestation may be more severe in males and elderly. Mild and non-progressive cases are more common, whereas moderate-to-severe forms account for only 5-6%.<sup>xlix</sup> Although GO is self-limiting in the majority of patients, it can be profoundly disabling.<sup>lii,liii</sup>

#### 3.3.1. Management of Graves' ophthalmopathy/ orbitopathy: <sup>xlix</sup>

The choice of treatment for Graves' ophthalmopathy/ orbitopathy is determined based on the clinical activity, severity, and disease duration since anti-inflammatory or immunosuppressive treatments are less effective after 18 months of disease duration.

Patients at risk of deterioration including clinically active Graves' ophthalmopathy/ orbitopathy, smokers, severe/unstable hyperthyroidism, and high serum thyrotropin receptor antibody (TSHR-Ab) titers must be referred to specialized centers with endocrine and ophthalmic expertise. All patients with Graves' hyperthyroidism, regardless of the presence or absence of Graves' ophthalmopathy/ orbitopathy should be encouraged to avoid smoking. Counselling and therapy options for moderate to severe, active Graves' ophthalmopathy/ orbitopathy (GO) should be discussed with the patients.

#### **Medical management:**

## **Comparison of different treatment modalities for Mild, Moderate-severe, and Severe Graves' ophthalmopathy/ orbitopathy (GO)**

**Mild Graves' ophthalmopathy/ orbitopathy (GO):**<sup>xlix</sup> Mild GO should be treated with local treatments and risk factor control measures. Mild and inactive GO can be treated based on the patient's preference along with the standardised criteria.

Patients with mild and active GO of recent onset should receive a 6-month selenium supplementation to improve eye-related manifestations and quality of life and prevent progression to more severe forms. Treatment with antithyroid drugs (ATDs) or thyroidectomy is recommended for hyperthyroidism; prophylactic treatment with prednisone/prednisolone may be considered only in patients undergoing RAI.

### **Moderate to severe Graves' ophthalmopathy/ orbitopathy (GO):**<sup>xlix</sup>

Mycophenolate sodium (or mofetil) is the primary treatment for moderate-to-severe and active GO. For moderate-to-severe and active GO, including constant and inconstant diplopia, severe inflammatory signs, and exophthalmos > 25 mm, intravenous (IV) methylprednisolone at the highest cumulative dose (7.5 g per cycle) as monotherapy is a valid first-line treatment.

A 1-year follow-up study of previously untreated patients with moderate-severe GO demonstrated that although a low dose of prednisolone was well tolerated, IV pulse methylprednisolone (0.5 g given thrice a month for 4 months) was more effective compared to oral prednisolone 1mg/kg/day for 6 weeks.<sup>liv</sup>

If primary treatment fails and there is no improvement in the severity of GO, second-line treatments after evaluating ocular and biochemical factors (liver enzymes) such as IV methylprednisolone monotherapy with high single doses (0.75 g) and a maximum cumulative dose of 8 g each cycle, oral prednisolone or prednisolone in combination with cyclosporine or azathioprine, orbital radiotherapy combined with oral or IV glucocorticoids, azathioprine rituximab, or tocilizumab are recommended for moderate-to-severe and active GO. Prednisone or prednisolone prophylaxis should be used if RAI treatment is chosen and in the presence of risk factors such as smoking and high TRAb levels.<sup>xlix</sup>

Li *et al.*<sup>lv</sup> performed a network meta-analysis to identify 15 trials in an attempt to compare the effects of various treatment modalities on active, moderate-to-severe GO. Intravenous glucocorticosteroids at low (4.5-5 g), moderate (6 g), and high (7-8 g) cumulative dosages

outperformed oral glucocorticosteroids in improving the overall response rate. They further validated that the cumulative low dose (4.5 - 5 g) was the most appropriate regimen during the evaluation of efficacy and safety outcomes. An average IV glucocorticoid dose of 3.8 g was reported by an Indian study by Gupta et al. that investigated visual morbidity in patients with GO.<sup>lvi</sup> Another meta-analysis consisting of 12 trials and 448 patients, suggested that tocilizumab provided significant reduction in proptosis and was a safe drug of choice followed by rituximab.<sup>lvii</sup>

For moderate-to-severe and active GO, ATDs should be used to manage hyperthyroidism until the treatment for GO treatment is completed.

### **Sight-threatening Graves' ophthalmopathy/ orbitopathy.<sup>xliv</sup>**

High doses of IV methylprednisolone (0.5-1 g daily for three days or every second day) should be administered immediately in patients with ophthalmic neuropathy. In case of a lack of improvement within 1-2 weeks, urgent orbital decompression is required to be performed. Further patients with recently developed ocular subluxation, should also undergo orbital decompression on an urgent basis. Severe corneal exposure should be rapidly treated medically or with more intrusive procedures to minimize progression to corneal breakdown, which if occurs should be surgically corrected immediately.

Due to the serious nature of the disease, treating GO should be prioritized while ATDs can be used to control hyperthyroidism during this period. ATD treatment given in the long term is beneficial in patients with GO due to decline of the serum TRAb levels as well as normalization of the thyroid function. Caution must be undertaken to avoid hypothyroidism of iatrogenic cause in such patients.<sup>lviii</sup>

S. No	Key Summary Point
20.	Patients at risk of deterioration including clinically active GO, smokers, severe/unstable hyperthyroidism, and high serum thyrotropin receptor antibody (TSHR-Ab) titers must be referred to combined thyroid-eye clinics or specialized centers with endocrine and ophthalmic expertise for an accurate and timely diagnosis to improve prognosis and quality of life
21.	Due to the serious nature of the disease, treating GO should be prioritized while ATDs can be used to control hyperthyroidism during this period. ATD treatment given in the long term is beneficial in patients with GO due to decline of the serum TRAb levels as well as normalization of the thyroid function.



22.	Patients with mild and active GO of recent onset should receive a 6-month selenium supplementation to improve eye-related manifestations and quality of life and prevent progression to more severe forms. Treatment with antithyroid drugs (ATDs) or thyroidectomy is recommended for hyperthyroidism;
23.	Mycophenolate sodium (or mofetil) is the primary treatment for moderate-to-severe and active GO. For moderate-to-severe and active GO, including constant and inconstant diplopia, severe inflammatory signs, and exophthalmos > 25 mm, intravenous (IV) methylprednisolone at the highest cumulative dose (7.5 g per cycle) as monotherapy is a valid first-line treatment.
24.	High doses of IV methylprednisolone (0.5-1 g daily for three days or every second day) should be administered immediately in patients with ophthalmic neuropathy. In case of a lack of improvement within 1-2 weeks, urgent orbital decompression should be performed. Further patients with recently developed ocular subluxation, should also undergo orbital decompression on an urgent basis. Severe corneal exposure should be rapidly treated medically or with more intrusive procedures to minimize progression to corneal breakdown, which should be surgically corrected immediately.

### 3.4 Multinodular Goiter

#### Diagnosis and assessment<sup>viii,xxxiv,lxx</sup>

Multinodular goiter can be characterized by subclinical hyperthyroidism for a long duration which precedes the development of clinical signs and symptoms. The clinical signs associated with multinodular goiter are milder compared to Graves' disease. Arrhythmia and atrial fibrillation are commonly associated with multi-nodular goiter. Thyroid scintigraphy scans are useful for assessing thyroid nodularity showing an uneven radionuclide distribution of numerous hyperfunctioning and cold nodules in toxic multinodular goiters (TMNG). Ultrasonography can help identifying the size and number of nodules whereas the colour doppler can estimate vascularity. To exclude malignancy in the cold nodules, FNAC may be indicated. CT and MRI may help to delineate retrosternal and recurrent enlargement of the thyroid gland.

#### Management Recommendations<sup>viii, xxxiv</sup>

##### Symptomatic treatment

Beta-adrenergic blockade is recommended in all symptomatic thyrotoxicosis patients, particularly those with resting heart rates over 90 bpm or coexisting cardiovascular disease. In patients with



bronchospastic asthma, where beta-blockers are generally contraindicated; alternatively, relative beta-1 selective agents can be used with careful monitoring. Calcium channel blockers like verapamil (240 mg oral or 5-10 mg intravenous)<sup>xxv</sup> or diltiazem (60 mg, orally four times a day)<sup>xxvi</sup> can be administered for rate control in patient's intolerant to or unsuitable for beta-blockers. Beta-blockers in asymptomatic patients who are at a high risk for complications is required if radioiodine is the mode of treatment. This is because the RAI may lead to a transient worsening of hyperthyroidism in patients with TMNG or TA.

#### Treatment for Multinodular Goiter

Treatment options include radioactive iodine (RAI), thyroidectomy, or low-dose anti-thyroid drugs in some cases. RAI and surgery swiftly eliminate hyperthyroidism, with RAI achieving 50%-80% response rates in TMNG. RAI is preferred in patients with older patients, prior surgery or scarring in the anterior neck, small goiter size, lack of access to surgery and a RAIU that is sufficient to allow therapy. Contraindications to RAI include pregnancy or women planning pregnancy within 6 months, lactation, coexisting thyroid cancer, patients who will not be able to follow the radiation safety guidelines.

Sufficient RAI in a single dose should be administered to alleviate hyperthyroidism in TMNG. Follow-up for thyroid function test (free T4, total T3 and TSH) is evaluated after RAI within 1-2 months of treatment. Thereafter, biochemical monitoring is at every 4 to 6 week intervals for 6 months. If the patient becomes hypothyroid, monitoring is continued till patient stabilized on thyroid hormone supplementation. If hyperthyroidism persists after 6 months, retreatment with RAI is suggested.

Surgery by a high-volume surgeon is preferred in patients who have compressive symptoms or signs, coexisting thyroid cancer concern, coexisting hyperparathyroidism that require surgery, a large goiter size (>80g), retrosternal or substernal extension, and patients who need immediate hyperthyroidism resolution. Surgery is not recommended in certain comorbidities such as cardiopulmonary disease, debilitating disorders such as cancer, and lack of access to a high volume surgeon. In pregnancy, surgery is second-line treatment if patient is uncontrolled on ATD or rapid control is required. Surgery should be considered in the second trimester of pregnancy.

If surgery is the chosen modality of treatment, pretreatment with ATD is required for achieving euthyroidism. Beta-blockers in surgery are required in symptomatic patients as well as patients at risk of complications. Beta-blockers can be slowly discontinued following the surgery. Near-total or total thyroidectomy is the preferred surgical approach. Post-thyroidectomy, serum calcium with or without iPTH levels should be measured. Based on the measured levels oral calcium and calcitriol supplementation may be needed.

After thyroidectomy, thyroid hormone supplementation must be initiated with TSH measured every 1-2 months until the patient is stable. Monitoring must be continued annually thereafter. In case of persistence of hyperthyroidism, RAI should be used for retreatment. For select patients in whom RAI or surgery are not feasible, alternative therapies such as ethanol or radiofrequency ablation may be considered, provided expertise in these procedures is available.

**Long-term Antithyroid drug<sup>lx</sup>** A clinical study compared the effectiveness of long-term methimazole (LT-MMI) versus radioactive iodine (RAI) treatment in managing hyperthyroidism in patients with toxic multinodular goiter (TMNG). The study demonstrated that LT-MMI therapy led to earlier attainment of euthyroidism and longer sustained normal serum thyrotropin levels compared to RAI treatment. Additionally, no major treatment-related adverse events were observed in either group.

### 3.5 Toxic Adenoma

#### **Diagnosis and assessment<sup>viii,xxxiii,xi</sup>**

Thyroid adenomas are sporadic in nature and occur more in females. Thyroid adenomas are associated with iodine deficiency. Around 1% of patients with thyroid adenoma have hyperthyroid symptoms. Commonly thyroid adenoma patients are asymptomatic, may have a visible or palpable thyroid mass, and rarely have dyspnea, dysphagia, and hoarseness of voice. Thyroid function tests, thyroid ultrasound(to distinguish adenoma from carcinoma- carcinoma may be identified by irregular margins, microcalcifications, hypoechogenicity, absent halo sign, and increased intramodular blood flow), fine needle aspiration biopsy(for adenoma with high suspicion of malignancy), iodine-123 (to distinguish between a hyperfunctioning and a hypofunctioning nodule) and genetic evaluation in some cases may be required for diagnostic evaluation.

#### **Management Recommendations<sup>viii,xxxiii,xi</sup>**

Symptomatic treatment will be similar to that of toxic multinodular goiters (TMNG).

### Treatment of Toxic Adenoma

RAI and surgery are the therapeutic options for toxic adenoma. Pretreatment with anti-thyroid drug and beta-blockers are needed in patients especially in those with high risk of complications.

RAI is preferred in patients with older patients, prior surgery or scarring in the anterior neck, small goiter size, lack of access to surgery and a RAIU that is sufficient to allow therapy. RAI needs to be given in a single sufficient dose. Follow-up for thyroid function test (free T4, total T3 and TSH) is evaluated after the RAI is within 1-2 months of treatment. Thereafter, biochemical monitoring is at every 4 to 6 week intervals for 6 months. If the patient becomes hypothyroid, monitoring is continued till patient stabilized on thyroid hormone supplementation. If hyperthyroidism persists after 6 months, retreatment with RAI is suggested. Surgery by a high-volume surgeon is preferred in patients who have compressive symptoms, need to avoid radiation, and need immediate hyperthyroidism resolution. Following evaluation via ultrasound, an ipsilateral thyroid lobectomy or isthmectomy is performed in cases of isolated thyroid adenomas. Post-surgical monitoring following lobectomy includes TSH and free T4 after 4-6 weeks. Persistent rise in TSH levels requires thyroid hormone supplementation. Hyperthyroid toxic adenoma may be treated with ATD in some cases.

S. No	Key Summary Point
25.	Thyroid scans are useful for assessing thyroid nodularity, with different patterns observed in toxic adenomas (TA), and toxic multinodular goiters (TMNG).
26.	In patients with TMNG and TA Beta-adrenergic blockade is recommended in all symptomatic thyrotoxicosis patients, particularly those with resting heart rates over 90 bpm or coexisting cardiovascular disease. Caution is advised in patients with bronchospastic asthma, where beta-blockers are generally contraindicated; In patients where RAI is the modality of treatment, beta-blockers is indicated even in asymptomatic patients and in patients at high risk of complications.
27.	MNG and TA patients with overt hyperthyroidism should be rendered euthyroid with carbimazole or methimazole before definitive treatment. The modality of treatment recommended are RAI, surgery or long term ATD.

#### 4. Thyroiditis

Thyroiditis exhibit a classic triphasic course: thyrotoxicosis, hypothyroidism, and recovery. Types of thyroiditis include subacute thyroiditis, painless (silent) thyroiditis, acute (suppurative) thyroiditis, palpation (traumatic) thyroiditis, postpartum thyroiditis, and drug-induced thyroiditis.

##### Subacute thyroiditis

Subacute thyroiditis (de Quervain thyroiditis), presents with thyroid pain, typically radiating to the ears, jaw, or throat. Diagnosis involves clinical history (malaise, low-grade fever, fatigue and history of viral infection), physical exam, lab tests, and radioactive iodine uptake. The thyroid may be slightly enlarged, firm, and tender. About 50% of cases have an initial thyrotoxic phase due to thyroid hormone release from damaged follicular cells lasting for 3–6 weeks, followed by a hypothyroid phase in about 30% of patients that can persist for up to 6 months and a return to a euthyroid state within 12 months. Five to fifteen percent may develop persistent hypothyroidism, and recurrence rates of 1%–4% have been reported.<sup>viii</sup>

Thyroid pain/tenderness, elevated erythrocyte sedimentation rate (ESR), hypoechoic ultrasound pattern, low uptake on thyroid scan, and specific findings on fine-needle aspiration can help in diagnosing subacute thyroiditis (SAT). Women are more predisposed to developing SAT and subsequent hypothyroidism.<sup>lxii</sup> Additional findings include presence of C-reactive protein levels, mild anemia and increased white blood cell (WBC) count. About 25% of patients may have reduced levels of antithyroid antibodies. Radioactive iodine uptake (RAIU) and thyroid scintigraphy results are low, with thyroid ultrasound showing diffuse heterogeneity, focal hypoechoic areas, and decreased or normal color flow Doppler.

Therapy for initial mild symptomatic subacute thyroiditis with beta-adrenergic-blocking drugs and nonsteroidal anti-inflammatory agents (NSAIDs) should be considered.<sup>viii</sup> Average time for pain resolution with NSAIDs is 5 weeks (with a range of 1–20 weeks). If patients do not respond to initial treatment with full dose of NSAID or present with moderate to severe pain and/or thyrotoxic symptoms, corticosteroids should be considered: prednisone at a dosage of 40 mg daily for 1–2 weeks, followed by a gradual taper over 2–4 weeks or longer based on individual clinical response. Antithyroid drugs (ATDs) are not recommended for the treatment of subacute thyroiditis.<sup>viii</sup>

### Painless thyroiditis

Painless or silent thyroiditis lacks the prodrome, neck pain, or elevated ESR, WBC count, or C-reactive protein. Commonly observed during the postpartum period, painless thyroiditis can also occur in nonpregnant women and men, as well as in certain drug-induced thyroid dysfunction cases such as those associated with lithium or cytokine therapy. A small, non-tender goiter is often present. 5%–20% of patients experience the thyrotoxic phase, lasting around 3–4 months, while the hypothyroid phase is more prevalent or more frequently identified, lasting up to 6 months. Most patients regain normal thyroid function within 12 months, but persistent hypothyroidism affects 10%–20% of individuals. Recurrence rates are approximately 5%–10%.<sup>viii</sup>

Painless thyroiditis likely represents an autoimmune disorder, as evidenced by the presence of positive anti-thyroid peroxidase antibodies in 50% of patients, along with lymphocytic infiltration histopathologically. <sup>viii</sup> Symptomatic individuals should receive treatment with beta-adrenergic-blocking drugs to alleviate symptoms. Antithyroid drugs (ATDs) are not effective in this context, as there is already minimal new hormone synthesis in these patients. In rare severe cases, corticosteroids may be considered as a therapeutic option.<sup>viii</sup>

### Acute thyroiditis

Treatment for acute thyroiditis involves antibiotics and surgery. Beta-blockers are required for symptomatic management. Patients identified with acute thyroiditis, also recognized as suppurative thyroiditis or thyroid abscess, commonly display normal thyroid function (euthyroid). Antithyroid drugs (ATDs) are not warranted in the treatment of this condition.<sup>viii</sup>

### Amiodarone Induced Thyrotoxicosis

Amiodarone induced thyroiditis is commonly (AIT) seen in iodine deficient regions and in the male gender. AIT presents with typical symptoms of hyperthyroidism except the cardiac symptoms may differ due to underlying condition. If a patient stable on amiodarone, suddenly undergoes re-emergence of cardiac condition such as worsening of atrial fibrillation and palpitation, AIT must be suspected. In some cases, cardiac symptoms are the only clinical evidence for AIT. Thyroid function testing is recommended to such a patient.<sup>lxiii, lxiv</sup>

There are two types of AIT: AIT 1 and AIT 2.

Amiodarone Induced Thyrotoxicosis 1 (AIT 1) often occurs when there is an underlying thyroid disease such as multinodular goiter or Graves' disease. AIT 1 is common in iodine deficient



regions. Since amiodarone contains iodine which may cause iodine excess and lead to increased thyroid hormone biosynthesis, AIT 1 may occur. AIT 1 usually appears after around three months of starting amiodarone. In the thyroid scintigraphy scans, I-131 uptake is high. In thyroid ultrasonography, a diffuse or nodular goiter pattern may be seen. Vascularity on Echo-color Doppler ultrasound is often increased. The T4/T3 ratio is  $<4$ . Antibodies such as TgAb, TPOAb and TSI may be present in AIT 1. Interleukin-6 levels are often normal. High dose ATD (methimazole – 30-40 mg/day; carbimazole 20-60 mg/day<sup>lxv, lxvi</sup> or propylthiouracil 400-600 mg/day) is given to block thyroid hormone synthesis. The dose is tapered to a low maintenance dose. ATDs are continued for the next 6 to 18 months and then discontinued based on the urine iodide levels. Amiodarone should be stopped if feasible. If amiodarone is continued, the patient must remain on the ATD. A modest response to ATD is expected since the iodine uptake levels are high. KClO<sub>4</sub> (potassium perchlorate) may be used to supplement the antithyroid drugs due to its iodine uptake blocking action. KClO<sub>4</sub> is associated with agranulocytosis or aplastic anemia, hence must be given  $< 1\text{g/day}$  and not more than 30 days. Lithium along with an ATD may also be given in cases of severe thyrotoxicosis for expedited recovery. Risk factors for severe thyrotoxicosis includes more than 23 months on amiodarone and thyroxine  $> 50\%$  above the upper limit of normal. RAI treatment can be considered if the radioiodine uptake is high. Possibility of overlap with AIT2 must be considered if there is worsening of the thyrotoxicosis after initial control of the disease.<sup>lxiii, lxiv</sup>

AIT 2 is a result of release of the preformed thyroid hormone due destruction of the thyroid tissue due to the toxic effect of amiodarone. AIT 2 may appear around 30 months after starting amiodarone. AIT 2 continues until the thyroid hormones depleted which occurs in 1-3 months. The ultrasonogram shows a normal or small gland and the T4/T3 ratio is usually  $>4$ . Antibodies are usually absent in AIT 2.<sup>lxiii</sup> Type 2 AIT is treated with glucocorticoids for anti-inflammatory and membrane stabilizing effects. Prednisolone can be given in the initial dose of 0.5 to 0.7 mg/kg body weight/day. Treatment is tapered and continued for three months. If worsening of the thyrotoxicosis during tapering of the treatment, then the dose of prednisolone should be increased. Anti thyroid drugs are not useful since the thyrotoxicosis is due to preformed thyroid hormones. After thyrotoxicosis resolution, hypothyroidism can develop which require thyroid hormone replacement therapy. Lithium may also benefit patients with AIT 2. Patients who do not respond



to medical management should consider total thyroidectomy under careful cardiovascular monitoring.<sup>lxiii, lxiv</sup>

S. No.	Key Summary Point
28.	Thyroiditis can be subacute, painless, acute, post-partum or drug induced. Diagnosis can be done by clinical history, physical examination, biochemical evaluation and radioactive iodine uptake. Symptomatic thyroiditis can be managed with the help of beta-blockers, NSAIDs and in some cases, corticosteroids.
29.	Amiodarone induced thyroiditis can be identified by RAIU, T4/T3 ratio, Echo color doppler. High dose ATD (carbimazole 20-60 mg/day) for 6 to 18 months is indicated in AIT type 1. Corticosteroids is indicated in AIT type 2.

### 5. Thyroid Storm<sup>ii, lxvii, lxviii</sup>

Thyroid storm or thyrotoxic crisis is life-threatening condition with high morbidity and mortality. A decompensation across multiple organ systems occur which can manifest as altered consciousness, cardiac complications such as heart failure, diarrhea, jaundice and high fever. Such patients may also have an identified precipitant:

- Stopping anti-thyroid drugs abruptly
- Thyroid or non-thyroid surgery
- Trauma
- Acute disease conditions such as diabetic ketoacidosis, acute myocardial infection, cardiac failure, cardiovascular accidents, stroke, traumatic brain injury and infections
- Use of iodinated contrast medium
- Hyperemesis gravidarum or after Parturition
- Burns
- Radioiodine therapy
- Drug side effects such as amiodarone

**Burch-Wartofsky Point Scale (BWPS)** measures the severity of the thyroid storm with a scoring system. A total score of  $\geq 45$  indicates thyroid storm, 25-44 as impending thyroid storm and  $< 25$  scores indicates that thyroid storm is unlikely.

- Temperature: 5 points per 1 F above 99 F (maximum 30 points)

- CNS dysfunction: 10 points for mild (agitation), 20 for moderate (delirium, psychosis, or extreme lethargy), and 30 for severe (seizure or coma)
- Tachycardia: 5 (99-109), 10 (110 -119), 15 (120 -129), 20 (130 -139) and 25 (greater than 140)
- Presence of atrial fibrillation:10
- Heart failure: 5 for mild (pedal edema), 10 for moderate (bi-basilar rales), 15 for severe (pulmonary edema)
- GI dysfunction: 10 for moderate (diarrhea, nausea/vomiting, or abdominal pain) and 20 for severe (unexplained jaundice)
- Presence of Precipitating factor: 10 points

An early and aggressive multimodal treatment is required. General management includes oxygen and cardiac monitoring. For pyrexia, external cooling or acetaminophen 325 -650 Per oral (PO) or Per rectal (PR) can be given. Intravenous isotonic saline (or dextrose containing isotonic saline can be used if low blood glucose present) Carbimazole 40 to 60 mg per oral as loading dose can be given followed by 5-20 mg daily as maintenance dose for inhibition of new thyroid hormone synthesis. Methimazole, 40 mg orally as initial loading dose and maintenance dose 25 mg every 4 hours. Total daily dose: 120 mg/day. If given PR, 40 mg should be crushed in aqueous solution. PTU, a loading dose of 600–1,000 mg given PO followed by 200–250 mg every 4 h. Total daily dose: 1,200–1,500 mg/day. Intravenous MMI 40 mg 8 hourly or PTU 400 mg 8 hourly to reduce thyroid hormone synthesis may be required.

To reduce the thyroid hormone release iodine is required. In order to block the peripheral conversion of T4 to T3, glucocorticoid, PTU, propranolol and iodinated radio contrast is required. Intravenous glucocorticoids such as i.v. methylprednisolone 50 mg or hydrocortisone 100 mg IV every 8 hours or dexamethasone 2 mg every 6 hours can be started. Beta-blockers to control the increased sympathetic tone such as propranolol 40 to 80 mg every 4-6 hours or short-acting beta-blocker esmolol at a loading dose of 250 mcg/kg to 500 mcg/kg followed by 50 mcg/kg to -100 mcg/kg/minute in an ICU setting can be given. Monitoring in the ICU is recommended. To reduce

enterohepatic cycling of thyroid hormone, bile acid sequestrant, cholestyramine in the doses of 4 mg four times daily is used.

PTU decreases T3 levels by 45% in the first 24 hours of treatment but may cause hepatotoxicity. Methimazole causes 10 -15% decrease in T3 levels in the first 24 hours but has less hepatotoxicity and hence PTU should be switched to methimazole after the initial stabilization.

Cause of death from thyroid storm is due to multi organ failure, heart and respiratory failure, arrhythmia, gastrointestinal perforation, sepsis, disseminated intravascular coagulation, and hypoxic brain syndrome.

S.No.	Key Summary Point
30.	The Burch-Wartofsky Point Scale system measures the severity of the thyroid storm. General management includes oxygen, cardiac monitoring, pyrexia management and Intravenous fluids. High dose antithyroid drugs, iodine, corticosteroids and beta-blockers are given to manage the thyrotoxicosis. ICU monitoring is recommended.

#### 6. Clinical Considerations for women of childbearing potential group:<sup>viii</sup>

Women in the childbearing potential group and who develop hyperthyroidism should receive proper counselling with special consideration on family planning. It is recommended that pregnancy test is done within the first days of a missed or an unusually light menstrual period and contact of physician within 24 hours if pregnancy is positive. Hyperthyroidism itself as well as the treatment for hyperthyroidism lead to untoward consequences in pregnancy and fetal outcome; therefore, women should reach euthyroid state before considering pregnancy. Two TFT test within an interval of at least 1 month and without therapy change is used to demonstrate euthyroidism. Definitive therapy of surgery and RAI should be considered in GD patients planning pregnancy who require high dose of ATD to become euthyroid. Thyroidectomy results in the decrease or disappearance of circulating TRAb. In case of RAI, there is an increase of transient TRAb and pregnancy must be considered in >6 months following RAI treatment, provided normalization of thyroid hormone levels. TRAb levels must be measured using sensitive assay during the first trimester and, if elevated levels are found there should be retesting at 18-22 weeks of gestation. If TRAb levels are raised at 18-22 weeks of gestation, TRAb should be retested at late pregnancy at week 30 to 34 in order to investigate need for neonatal monitoring.

### 6.1. Hyperthyroidism in Pregnancy and Lactation

Overt hyperthyroidism in pregnancy is diagnosed with the help of thyroid function test with TSH  $<0.1\text{mIU/L}$  and thyroid hormones (free T4 and free T3) that are above the reference ranges for pregnancy.<sup>lxix, lxx</sup>

In pregnancy, the maternal thyroid gland undergoes several physiological alterations. Gestational transient thyrotoxicosis (GTT) is a condition where hCG produced by the placenta induces the TSH receptor to produce thyroid hormones T3 and T4. Compared to a non-pregnant woman, the serum concentration of TSH is also reduced. GTT presents with symptoms similar to GD such as anxiety, tremors, palpitations and heat intolerance. In conditions with exaggerated hCG production, such as in trophoblastic disease, hyperemesis gravidarum or multiple pregnancies, the GTT symptoms can be severe.<sup>lxxi, lxxii, lxxiii,</sup>

It is necessary to distinguish GTT from GD. GTT is a transient condition and mild in nature and therefore does not require treatment with ATD. Graves' disease is associated with maternal and fetal adverse outcomes and hence, needs careful management with appropriate ATDs and monitoring. TRABs are of special significance in such cases since positive TRAb can help confirm Graves' disease and can differentiate from the gestational transient thyrotoxicosis. Presence of Graves' orbitopathy, goiter and previous GH are also indicative of the diagnosis of Graves' disease.<sup>lxxi, lxxii, lxxiv</sup> It is important to elicit a history of Graves' disease in pregnant women who have underwent radioiodine ablation treatment or surgery, since the circulating TRAb may persist and lead to fetal thyrotoxicosis.<sup>viii</sup>

Propylthiouracil is preferred in the first trimester due to the association of methimazole and carbimazole with choanal atresia, aplasia cutis, abdominal wall defects, esophageal atresia, eye abnormalities, urinary tract abnormalities and defects in circulation. After the first trimester, the patient can be transitioned to carbimazole or methimazole since propylthiouracil is associated with hepatotoxicity.<sup>lxxi</sup> In case of intolerance or allergy to propylthiouracil, the patient may be given carbimazole or methimazole. The lowest possible anti-thyroid dose for maintaining effectiveness must be used.<sup>lxxv, lxx</sup>

Maternal TRABs can cross placenta and stimulate the fetal thyroid gland causing fetal hyperthyroidism. ATDs can cross placenta and control the fetal hyperthyroidism. A caution must

be undertaken to prevent fetal hypothyroidism while the patient is on ATD. Therefore, the goal of treatment is to use the lowest ATD dose in order to target the TSH to a value that is slightly lower than the reference range and a T4 that is on the higher end of the normal reference range. Beta-blockers such as propranolol may provide symptomatic relief. Propranolol is preferred over atenolol due to decreased birth weight being associated with atenolol. Beta-blockers must always be given for a short term. Long term beta-blockers may increase the risk of intrauterine fetal growth retardation. Iodides are contraindicated due to risk of fetal goiter.<sup>viii,xxxv</sup>

In cases of Graves' disease treated with thyroidectomy or RAI, maternal euthyroidism combined with positive TRAb test can be seen in pregnancy. In such cases, TRAb evaluation must be done in the first trimester along with the thyroid function test. If the TRAb levels are elevated at first trimester evaluation, a reassessment must be done at 18 to 22 weeks of gestation. Elevated TRAb levels may lead to fetal thyrotoxicosis and can be detected clinically by fetal tachycardia (Fetal heart rate >160). Re-evaluation should occur be done in 2 weeks with the help of fetal ultrasound (improvement in fetal heart rate and resolution of goiter) In such cases block-replace regimen of antithyroid drugs can treat fetal thyrotoxicosis since ATDs can cross placenta while levothyroxine which does not cross placenta can maintain maternal euthyroidism. In patients with raised TRAb levels at 18-22 weeks, the TRAb levels need to be reassessed at 30 to 34 weeks to guide clinical decision related to neonates.<sup>viii</sup>

In pregnant women with toxic multinodular goiter or toxic adenoma, anti-thyroid drugs may be given. Adequate care must be undertaken to prevent fetal hypothyroidism in such cases since unlike Graves' disease, TRAb are not present to stimulate the thyroid gland.<sup>viii</sup>

In women developing thyrotoxicosis in the post-partum period, there is need to distinguish post-partum destructive thyroiditis and post-partum Graves' disease. Postpartum thyroiditis follows the triphasic course: thyrotoxicosis emerging at 1-6 months postpartum, followed by hypothyroidism and euthyroidism at 9 to 12 months. Symptomatic post-partum thyroiditis should be managed with a short course of beta-blockers. Postpartum GD emerges at 3 to 12 months after delivery and may be characterized by pronounced goiter, thyroid bruit and Graves' ophthalmopathy. While TRAb may be present in patients with both postpartum thyroiditis and postpartum Graves' disease, higher TRAb levels may be present in women with postpartum GD. T3 to T4 ratio is high in Graves' disease relative to destructive thyroiditis. Thyroid ultrasonography may be adopted to distinguish



Graves' disease and thyroiditis. Radioactive scintigraphy scans to diagnose the cause of postpartum thyrotoxicosis should be avoided to prevent exposure to radiation.<sup>viii</sup>

## Management of Hyperthyroidism in Lactation

### Use of Anti-Thyroid Drug in lactation<sup>lxxvi,lxxvii</sup>

Carbimazole has been studied in doses of 30 mg daily or 50 mg weekly in few mothers of breastfed infants and has not shown any adverse effects. Methimazole in doses up to 20 mg daily in lactating mother has not been seen to affect the thyroid function or intellectual development of breastfed infants. To minimize the infant dose, methimazole can be taken right after nursing and waiting for 3 to 4 hours before nursing. Beta-blockers such as propranolol and metoprolol are secreted in the breast milk in very low amounts and can be used for symptomatic control of thyrotoxicosis. Routine pediatric health monitoring must be undertaken for infants for growth and development. Routine thyroid function test is not recommended for children. Suspicion of drug-induced dyscrasia should be confirmed with the monitoring of infant's complete blood count and differential blood count

S. No	Key Summary Point
31.	Proper counselling is required in women with hyperthyroidism since the condition of hyperthyroidism itself as well as the treatment for hyperthyroidism lead to untoward consequences in pregnancy and fetal outcome.
32.	Women should reach euthyroid state before considering pregnancy. Two TFT test within an interval of at least 1 month and without therapy change is used to demonstrate euthyroidism
33.	Definitive therapy of surgery and RAI should be considered in women with hyperthyroidism desirous of pregnancy who required high dose of ATD to become euthyroid. In case of RAI, there is an increase of transient TRAb, and pregnancy must be considered in >6 months following RAI treatment, provided normalization of thyroid hormone levels.
34.	In pregnancy the cause of hyperthyroidism is not ascertained, TRAb testing must be done
35.	Once pregnancy is confirmed, hyperthyroid patient can switch to PTU before conceiving or as soon as pregnancy is diagnosed. After first trimester, patient can be switched to carbimazole or methimazole in the second trimester or can be continued for the rest of the pregnancy



36.	Thyroidectomy is relatively contraindicated in pregnancy and is utilized if ATDs are contraindicated; if this approach is used, surgery should be conducted in the second trimester
37.	Antithyroid may be given in lactating mothers. To minimize the infant dose, anti-thyroid drug can be taken right after nursing and waiting for 3 to 4 hours before nursing. Routine pediatric health monitoring must be undertaken for infants for growth and development. Suspicion of drug-induced dyscrasia should be confirmed with the monitoring of infant's complete blood count and differential blood count

## REFERENCES

- <sup>i</sup> Idrose AM. Acute and emergency care for thyrotoxicosis and thyroid storm. *Acute Med Surg*. 2015 May 12;2(3):147-157. doi: 10.1002/ams2.104.
- <sup>ii</sup> Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism. *Eur Thyroid J*. 2018 Aug;7(4):167-186. doi: 10.1159/000490384.
- <sup>iii</sup> Doubleday AR, Sippel RS. Hyperthyroidism. *Gland Surg*. 2020 Feb;9(1):124-135. doi: 10.21037/gs.2019.11.01.
- <sup>iv</sup> Wiersinga WM, Poppe KG, Effraimidis G. Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis. *Lancet Diabetes Endocrinol*. 2023 Apr;11(4):282-298. doi: 10.1016/S2213-8587(23)00005-0. Epub 2023 Feb 24. PMID: 36848916.
- <sup>v</sup> Nijith L, Ranjan R. Cardiovascular Manifestations in Hyperthyroidism: A Cross-Sectional Study in a Tertiary Care Hospital in South India. *Cureus*. 2022 May 23;14(5):e25232. doi: 10.7759/cureus.25232. PMID: 35755496; PMCID: PMC9217679.
- <sup>vi</sup> Agrawal PG, Khopkar US, Mahajan SA, Mishra SN. Triads in dermatology. *Indian J Dermatol*. 2013 Sep;58(5):346-51. doi: 10.4103/0019-5154.117297.
- <sup>vii</sup> Medeiros-Neto G. Multinodular Goiter. [Updated 2016 Sep 26]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. *Endotext* [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK285569/>
- <sup>viii</sup> Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. *Thyroid*. 2016 Oct;26(10):1343-1421. doi: 10.1089/thy.2016.0229. Erratum in: *Thyroid*. 2017 Nov;27(11):1462.
- <sup>ix</sup> Mulita F, Anjum F. Thyroid Adenoma. [Updated 2023 Apr 27]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK562252/>
- <sup>x</sup> Fariduddin MM, Singh G. Thyroiditis. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK555975/>
- <sup>xi</sup> Werner & Ingbar's The Thyroid: A Fundamental and Clinical Text, 10th Edition page number 496
- <sup>xii</sup> Orgiazzi J, Millot L. Aspects théoriques du traitement par les antithyroïdiens [Theoretical aspects of the treatment with antithyroid drugs]. *Ann Endocrinol (Paris)*. 1994;55(1):1-5. French. PMID: 7528484.
- <sup>xiii</sup> Goswami R, Seth A, Goswami AK, Kochupillai N. Prevalence of enuresis and other bladder symptoms in patients with active Graves' disease. *Br J Urol*. 1997 Oct;80(4):563-6. doi: 10.1046/j.1464-410x.1997.00426.x. PMID: 9352693.
- <sup>xiv</sup> Wu W, Sun Z, Yu J, Meng Q, Wang M, Miao J, Sun L. A clinical retrospective analysis of factors associated with apathetic hyperthyroidism. *Pathobiology*. 2010;77(1):46-51. doi: 10.1159/000272954. Epub 2010 Feb 25. PMID: 20185967.
- <sup>xv</sup> Blick C, Nguyen M, Jialal I. Thyrotoxicosis. [Updated 2023 Jul 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK482216/>

- xvi Kim HJ. Long-term management of Graves disease: a narrative review. *J Yeungnam Med Sci.* 2023 Jan;40(1):12-22. doi: 10.12701/jyms.2022.00444. Epub 2022 Nov 4. PMID: 36329661; PMCID: PMC9946914.
- xvii Barbesino G, Tomer Y. Clinical review: Clinical utility of TSH receptor antibodies. *J Clin Endocrinol Metab.* 2013 Jun;98(6):2247-55. doi: 10.1210/jc.2012-4309. Epub 2013 Mar 28. PMID: 23539719; PMCID: PMC3667257.
- xviii Nguyen CT, Mestman JH. Graves' hyperthyroidism in pregnancy. *Current Opinion in Endocrinology, Diabetes and Obesity.* 2019 Oct 1;26(5):232-40
- xix Nguyen, C.T., Sasso, E.B., Barton, L. et al. Graves' hyperthyroidism in pregnancy: a clinical review. *Clin Diabetes Endocrinol* 4, 4 (2018). <https://doi.org/10.1186/s40842-018-0054-7>
- xx Diana T, Ponto KA, Kahaly GJ. Thyrotropin receptor antibodies and Graves' orbitopathy. *Journal of Endocrinological Investigation.* 2021;44:703-12
- xxi Lee SY, Pearce EN. Hyperthyroidism: A Review. *JAMA.* 2023 Oct 17;330(15):1472-1483. doi: 10.1001/jama.2023.19052. PMID: 37847271; PMCID: PMC10873132.
- xxii Lee SY, Pearce EN. Hyperthyroidism: A Review. *JAMA.* 2023 Oct 17;330(15):1472-1483. doi: 10.1001/jama.2023.19052. PMID: 37847271; PMCID: PMC10873132.
- xxiii Giovannella L. Update on diagnosis and treatment of hyperthyroidism. *Q J Nucl Med Mol Imaging.* 2021 Jun;65(2):89-90. doi: 10.23736/S1824-4785.21.03351-3. Epub 2021 Feb 26. PMID: 33634674.
- xxiv Matkowski B, Serafin Z, Glonek R, Suwała S, Łopatto R, Junik R. The Role of 18F-FDG PET/CT in the Management of the Autoimmune Thyroid Diseases. *Front Endocrinol (Lausanne).* 2019 Apr 5;10:208. doi: 10.3389/fendo.2019.00208. PMID: 31024448; PMCID: PMC6460940.
- xxv Verapamil Controls Atrial Fibrillation Associated with Hyperthyroidism. *Inpharma Wkly.* 592, 13 (1987). <https://doi.org/10.1007/BF03291396>
- xxvi MILNER MR, GOLDMAN ME. Diltiazem for the Treatment of Thyrotoxicosis. *Arch Intern Med.* 1989;149(5):1217. doi:10.1001/archinte.1989.00390050163038
- xxvii Rivas AM, Pena C, Kopel J, Dennis JA, Nugent K. Hypertension and hyperthyroidism: association and pathogenesis. *The American Journal of the Medical Sciences.* 2021 Jan 1;361(1):3-7.
- xxviii Abraham P, Acharya S. Current and emerging treatment options for Graves' hyperthyroidism. *Ther Clin Risk Manag.* 2010 Feb 2;6:29-40. doi: 10.2147/tcrm.s5229. PMID: 20169034; PMCID: PMC2817786;
- xxix Geffner DL, Hershman JM. Beta-adrenergic blockade for the treatment of hyperthyroidism. *Am J Med.* 1992 Jul;93(1):61-8. doi: 10.1016/0002-9343(92)90681-z. PMID: 1352658.
- xxx Baek HS, Lee J, Jeong CH, Lee J, Ha J, Jo K, Kim MH, Cho JH, Kang MI, Lim DJ. The Prediction Model Using Thyroid-stimulating Immunoglobulin Bioassay For Relapse of Graves' Disease. *J Endocr Soc.* 2022 Feb 16;6(5):bvac023. doi: 10.1210/jendso/bvac023. PMID: 35441120; PMCID: PMC9012332
- xxxi MOTASHAW MD. Treatment of angina pectoris with antithyroid drug (Carbimazole). *J Assoc Physicians India.* 1963 Apr;11:293-8.
- xxxii Kalra, Sanjay; Bajaj, Sarita1; Mithal, Ambrish2. Endocrinology and the essential list. *Indian Journal of Endocrinology and Metabolism* 16(Suppl 2):p S133-S135, December 2012
- xxxiii Thyroid disease: assessment and management. London: National Institute for Health and Care Excellence (NICE); 2019 Nov 20. PMID: 31829541.
- xxxiv Davies, T.F., Andersen, S., Latif, R. et al. Graves' disease. *Nat Rev Dis Primers* 6, 52 (2020). <https://doi.org/10.1038/s41572-020-0184-y>
- xxxv Burch HB, Cooper DS. ANNIVERSARY REVIEW: Antithyroid drug therapy: 70 years later. *Eur J Endocrinol.* 2018 Oct 12;179(5):R261-R274. doi: 10.1530/EJE-18-0678. PMID: 30320502.
- xxxvi NEW ZEALAND DATA SHEET Carbimazole 5 mg accessed from Neo-Mercazoletab.pdf (medsafe.govt.nz) on 31st January 2024
- xxxvii Cooper DS. Antithyroid drugs in the management of patients with Graves' disease: an evidence-based approach to therapeutic controversies. *The Journal of Clinical Endocrinology & Metabolism.* 2003;88(8):3474-81.
- xxxviii MacFarlane IA, Davies D, Longson D, Shalet SM, Beardwell CG. Single daily dose short term carbimazole therapy for hyperthyroid Graves' disease. *Clin Endocrinol (Oxf).* 1983 Jun;18(6):557-61. doi: 10.1111/j.1365-2265.1983.tb00593.x. PMID: 6411390

- xxxix Gupta SK, Mithal A, Godbole MM. Single daily dose of carbimazole in the treatment of hyperthyroidism. *Natl Med J India*. 1992 Sep-Oct;5(5):214-6. PMID: 1302580
- xl Gilbert J. Thyrotoxicosis—investigation and management. *Clinical Medicine*. 2017 Jun;17(3):274.
- xli Yap PK. Single daily dose carbimazole in the treatment of Grave's disease. *Singapore Med J*. 1979 Dec;20(4):447-50. PMID: 583526
- xlvi Morales García F, Cayuela A, García Hernández N, Losada Viñau F, Mangas Cruz MÁ, Martínez Brocca MA, Navarro González E, Pumar López A, Relimpio Astolfi F, Soto Moreno A, Villamil Fernández F. Long-term maintenance of low-dose antithyroid drugs versus drug withdrawal in patients with Graves' hyperthyroidism. *Endocrinol Nutr*. 2008 Mar;55(3):123-31.
- xlvi Azizi F, Mehran L, Abdi H, Amouzegar A. Approach to the Patient Considering Long-term Antithyroid Drug Therapy for Graves' Disease. *J Clin Endocrinol Metab*. 2024 Sep 16;109(10):e1881-e1888. doi: 10.1210/clinem/dgae456. PMID: 39018185.
- xlv Azizi F, Abdi H, Mehran L, Amouzegar A. Appropriate duration of antithyroid drug treatment as a predictor for relapse of Graves' disease: a systematic scoping review. *J Endocrinol Invest*. 2022 Jun;45(6):1139-1150. doi: 10.1007/s40618-021-01730-1. Epub 2022 Jan 28. PMID: 35088381.
- xlv Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, Marinò M, Vaidya B, Wiersinga WM; EUGOGO †. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. *Eur J Endocrinol*. 2021 Aug 27;185(4):G43-G67. doi: 10.1530/EJE-21-0479.
- xlvi Campbell K, Doogue M. Evaluating and managing patients with thyrotoxicosis. *Australian family physician*. 2012 Aug;41(8):564-72.
- xlvii Stockigt JR. Thyroid dysfunction and goiter: therapeutic dilemmas. *Australian Prescriber*. 1994;17(3).
- xlviii Azizi F, Abdi H, Amouzegar A. Control of Graves' hyperthyroidism with very long-term methimazole treatment: a clinical trial. *BMC Endocr Disord*. 2021 Jan 14;21(1):16. doi: 10.1186/s12902-020-00670-w. PMID: 33446181; PMCID: PMC7807686.
- xlix Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, Marinò M, Vaidya B, Wiersinga WM; EUGOGO †. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. *Eur J Endocrinol*. 2021 Aug 27;185(4):G43-G67.
- xlix Campbell K, Doogue M. Evaluating and managing patients with thyrotoxicosis. *Aust Fam Physician*. 2012 Aug;41(8):564-72. PMID: 23145395
- xlix Stockigt J. Thyroid dysfunction and goiter: therapeutic dilemmas. *Aust Prescr* 1994;17:70-2. <https://doi.org/10.18773/austprescr.1994.062>
- xlix Burch HB, Cooper DS. Management of Graves Disease: A Review. *JAMA*. 2015 Dec 15;314(23):2544-54. doi: 10.1001/jama.2015.16535. Erratum in: *JAMA*. 2016 Feb 9;315(6):614. PMID: 26670972.
- xlix Santos Palacios S, Pascual-Corrales E, Galofre JC. Management of subclinical hyperthyroidism. *Int J Endocrinol Metab*. 2012 Spring;10(2):490-6. doi: 10.5812/ijem.3447. Epub 2012 Apr 20. PMID: 23843809; PMCID: PMC369361
- 6.
- xlix Burch HB, Cooper DS. Management of Graves Disease: A Review. *JAMA*. 2015 Dec 15;314(23):2544-54. doi: 10.1001/jama.2015.16535. Erratum in: *JAMA*. 2016 Feb 9;315(6):614. PMID: 26670972.
- <sup>1</sup> Santos Palacios S, Pascual-Corrales E, Galofre JC. Management of subclinical hyperthyroidism. *Int J Endocrinol Metab*. 2012 Spring;10(2):490-6. doi: 10.5812/ijem.3447. Epub 2012 Apr 20. PMID: 23843809; PMCID: PMC369361
- 6.
- <sup>ii</sup> Mohan A, Joseph S, Sidharthan N, Murali D. Carbimazole-induced agranulocytosis. *J Pharmacol Pharmacother*. 2015 Oct-Dec;6(4):228-30. doi: 10.4103/0976-500X.171881. PMID: 26813922; PMCID: PMC4714394.
- <sup>iii</sup> Fernandes AS. Update on Graves' ophthalmopathy (Doctoral dissertation).
- <sup>iiii</sup> Reddy SV, Jain A, Yadav SB, Sharma K, Bhatia E. Prevalence of Graves' ophthalmopathy in patients with Graves' disease presenting to a referral centre in north India. *Indian J Med Res*. 2014;139(1):99-104.
- <sup>liv</sup> Roy A, Dutta D, Ghosh S, Mukhopadhyay P, Mukhopadhyay S, Chowdhury S. Efficacy and safety of low dose oral prednisolone as compared to pulse intravenous methylprednisolone in managing moderate severe

Graves' orbitopathy: A randomized controlled trial. *Indian J Endocrinol Metab.* 2015 May-Jun;19(3):351-8. doi: 10.4103/2230-8210.152770

<sup>lv</sup> Li H, Yang L, Song Y, Zhao X, Sun C, Zhang L, Zhao H, Pan Y. Comparative effectiveness of different treatment modalities for active, moderate-to-severe Graves' orbitopathy: a systematic review and network meta-analysis. *Acta Ophthalmologica.* 2022;100(6):e1189-98.

<sup>lvi</sup> Gupta R, Thomas R, Almkhatar F, Kiran A. Visual morbidity in thyroid eye disease in Asian Indian patients. *Indian Journal of Ophthalmology.* 2020;68(8):1622-7.

<sup>lvii</sup> Hu Y, Chen J, Lin K, Yu X. Efficacy and Safety of intravenous monoclonal antibodies in patients with moderate-to-severe active Graves' ophthalmopathy: a systematic review and meta-analysis. *Front Endocrinol (Lausanne).* 2023 May 23;14:1160936. doi: 10.3389/fendo.2023.1160936.

<sup>lviii</sup> Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, Marinò M, Vaidya B, Wiersinga WM; EUGOGO †. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. *Eur J Endocrinol.* 2021 Aug 27;185(4):G43-G67. doi: 10.1530/EJE-21-0479.

<sup>lix</sup> Jerusha TR, Harshitha VS, Rekha B, Swetha P, Balaprabha GR, Rao R. Multinodular Goiter. *Journal homepage: www.ijrpr.com* ISSN.;2582:7421.

<sup>lx</sup> Azizi F, Saadat N, Takyar MA, Abdi H, Mehran L, Amouzegar A. Efficacy and Safety of Long-Term Methimazole versus Radioactive Iodine in the Treatment of Toxic Multinodular Goiter. *Endocrinol Metab (Seoul).* 2022 Dec;37(6):861-869. doi: 10.3803/EnM.2022.1476.

<sup>lxi</sup> Mulita F, Anjum F. Thyroid Adenoma. [Updated 2023 Apr 27]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK562252/>

<sup>lxii</sup> Görges J, Ulrich J, Keck C, Müller-Wieland D, Diederich S, Janssen OE. Long-term outcome of subacute thyroiditis. *Experimental and Clinical Endocrinology & Diabetes.* 2020 Nov;128(11):703-8.

<sup>lxiii</sup> Tsang W, Houlden RL. Amiodarone-induced thyrotoxicosis: a review. *Can J Cardiol.* 2009 Jul;25(7):421-4. doi: 10.1016/s0828-282x(09)70512-4. PMID: 19584973; PMCID: PMC2723027.

<sup>lxiv</sup> Macchia PE, Feingold KR. Amiodarone Induced Thyrotoxicosis. [Updated 2022 Jun 1]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. *Endotext* [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK279030/>

<sup>lxv</sup> Osman F, Franklyn JA, Sheppard MC, Gammage MD. Successful treatment of amiodarone-induced thyrotoxicosis. *Circulation.* 2002 Mar 19;105(11):1275-7. PMID: 11901034.

<sup>lxvi</sup> Arnold A 2017 Primary hyperparathyroidism: molecular genetic insights and clinical implications. Presented at Society for Endocrinology BES 2017, Harrogate, UK. *Endocrine Abstracts* 50 PL1

<sup>lxvii</sup> Pokhrel B, Aiman W, Bhusal K. Thyroid Storm. [Updated 2022 Oct 6]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK448095/>

<sup>lxviii</sup> Idrose AM. Acute and emergency care for thyrotoxicosis and thyroid storm. *Acute Med Surg.* 2015 May 12;2(3):147-157. doi: 10.1002/ams2.104. PMID: 29123713; PMCID: PMC5667251.

<sup>lxix</sup> Indian Thyroid Society. 2019 Recommendations for the management of Thyroid dysfunction in pregnancy. Accessed from [https://www.indianthyroidsociety.in/assets/img/guidelines/ITS\\_FOGSI\\_Recommendations.pdf](https://www.indianthyroidsociety.in/assets/img/guidelines/ITS_FOGSI_Recommendations.pdf) on 7th February 2025

<sup>lxx</sup> Indian thyroid society in collaboration with the endocrine society in India. Guidelines for management of thyroid dysfunction during pregnancy. Accessed from [https://www.indianthyroidsociety.in/assets/img/guidelines/Maternal\\_Thyroid\\_Guidelines.pdf](https://www.indianthyroidsociety.in/assets/img/guidelines/Maternal_Thyroid_Guidelines.pdf) on 7th February 2025

<sup>lxxi</sup> Sorah K, Alderson TL. Hyperthyroidism in Pregnancy. [Updated 2023 May 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK559203/>

<sup>lxxii</sup> Cooper DS, Laurberg P. Hyperthyroidism in pregnancy. *Lancet Diabetes Endocrinol.* 2013 Nov;1(3):238-49. doi: 10.1016/S2213-8587(13)70086-X. Epub 2013 Oct 18. PMID: 24622372.

<sup>lxxiii</sup> Iijima S. Pitfalls in the assessment of gestational transient thyrotoxicosis. *Gynecol Endocrinol.* 2020 Aug;36(8):662-667. doi: 10.1080/09513590.2020.1754391. Epub 2020 Apr 17. PMID: 32301638.

© 2025 Indian Thyroid Society. All rights reserved.

This material is protected by copyright law and may not be reproduced, distributed, transmitted, displayed, published, or broadcast without prior written permission of the copyright owner.



<sup>lxxiv</sup> Nguyen CT, Sasso EB, Barton L, Mestman JH. Graves' hyperthyroidism in pregnancy: a clinical review. Clin Diabetes Endocrinol. 2018 Mar 1;4:4. doi: 10.1186/s40842-018-0054-7. PMID: 29507751; PMCID: PMC5831855.

<sup>lxxv</sup> Singh S, Sandhu S. Thyroid Disease and Pregnancy. [Updated 2023 Jul 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK538485/>

<sup>lxxvi</sup> Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Methimazole. [Updated 2020 Dec 21]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK501024/>

<sup>lxxvii</sup> Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Carbimazole. [Updated 2022 Jun 20]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK501759/>

